CalciMedica Subsidiary
La Jolla, US · Delaware corporation · 1 known investors
Find your way into CalciMedica Subsidiary
77 people in our graph share verified history with the CalciMedica Subsidiary team — schools, employers, funds. One of them is your warm intro.
Tom Stephensonunlockedknows Sudarshan Hebbar · together at University of Chicago (overlapped)
×6knows the team · via University of Chicago
×2knows the team · via The Johns Hopkins University
×2knows the team · via Tulane University School of Medicine
knows the team · via Oncimmune
Founders & leadership
DG
Daniel GeffkenExecutive
SH
Sudarshan HebbarinExecutiveSudarshan Hebbar is an Executive Officer at CalciMedica Subsidiary with over 12 years of medical practice in nephrology and critical care, alongside 8+ years of experience in global clinical and product development for diagnostics and therapeutics.
EW
Eric W. RobertsExecutive
KA
Kenneth A. StaudermanNamed on SEC filing
MJ
Michael J. DunnNamed on SEC filing
Board
AR
A. Rachel LehenyBoard director
BG
Brian GallagherBoard director
VG
Vikas GoyalBoard director
JM
John McDonaldBoard director
PM
TW
Timothy WollaegerBoard directorManaging Director Emeritus at Sanderling Ventures
EG
Evelyn GrahamBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$30M disclosed across 3 rounds · 2014–2023
▶$10.3MraisedApr 2023 · 8 investors · BiotechnologyRule 506(b)
▶$10.3MraisedApr 2023 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kenneth A. StaudermanExecutive Officer
- A. Rachel LehenyExecutive Officer, Director
- Daniel GeffkenExecutive Officer
- Sudarshan HebbarExecutive Officer
- Eric W. RobertsExecutive Officer
- Michael J. DunnExecutive Officer, Director
- Offering amount
- $10.3M
- Amount sold
- $10.3M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$17.2MraisedMay 2020 · 12 investors · BiotechnologyRule 506(b)
▶$17.2MraisedMay 2020 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert G. McNeilDirector
- Lakmir ChawlaDirector
- A. Rachel LehenyExecutive Officer, Director
- Fred MiddletonDirector
- Robert WilsonDirector
- Eric RobertsExecutive Officer, Director
- Michael DunnExecutive Officer, Director
- Offering amount
- $17.2M
- Amount sold
- $17.2M
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedApr 2014 · 5 investors · BiotechnologyRule 506(b)
▶$2.5MraisedApr 2014 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brian GallagherDirector
- Michael DunnExecutive Officer, Director
- Vikas GoyalDirector
- Ken StaudermanExecutive Officer
- John McDonaldDirector
- Peter McWilliamsDirector
- Timothy WollaegerDirector
- Evelyn GrahamDirector
- Offering amount
- $13.1M
- Amount sold
- $2.5M
- First sale
- Apr 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are CalciMedica Subsidiary's investors?
- CalciMedica Subsidiary's investors include Sanderling Ventures.
- How much funding has CalciMedica Subsidiary raised?
- CalciMedica Subsidiary has disclosed $30M raised across 3 rounds.
- Where is CalciMedica Subsidiary headquartered?
- CalciMedica Subsidiary is headquartered in La Jolla, US.